Selected Characteristics of SARS-CoV-2 Variants of Concern+,,,,,,,,
Name (Pango lineageexternal icon)a,Spike Protein Substitutions,Name (Nextstrainexternal iconexternal icon)b,WHO Labelc,First Detected,BEIexternal iconReference Isolatec,Attributesd,,
B.1.1.7,"69del, 70del, 144del, (E484K*), (S494P*), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H (K1191N*)",20I/501Y.V1,Alpha,United Kingdom,NR-54000external icon,,"~50% increased transmission 5. Potential increased severity based on hospitalizations and case fatality rates 6. No impact on susceptibility to EUA monoclonal antibody treatments 7,14. Minimal impact on neutralization by convalescent and post-vaccination sera 8,9,10,11,12,13,19",
B.1.351,"D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, A701V",20H/501.V2,Beta,South Africa,NR-55282external icon,,"~50% increased transmission16. Significantly reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment,7 but other EUA monoclonal antibody treatments are available 14. Reduced neutralization by convalescent and post-vaccination sera 8,12,18,19,20",
B.1.427,"L452R, D614G",20C/S:452R,Epsilon,United States-(California),,,"~20% increased transmissibility 21. Modest decrease in susceptibility to the combination of bamlanivimab and etesevimab; however, the clinical implications of this decrease are not known.7Alternative monoclonal antibody treatments are available.14 Reduced neutralization by convalescent and post-vaccination sera 21",
B.1.429,"S13I, W152C, L452R, D614G",20C/S:452R,Epsilon,United States-(California),,,"~20% increased transmissibility 21. Reduced susceptibility to the combination of bamlanivimab and etesevimab; however, the clinical implications of this decrease are not known.7Alternative monoclonal antibody treatments are available 14. Reduced neutralization by convalescent and post-vaccination sera 21.",
P.1,"L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I",20J/501Y.V3,Gamma,Japan/Brazil,NR-54982external icon,,"Significantly reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment,7 but other EUA monoclonal antibody treatments are available 14. Reduced neutralization by convalescent and post-vaccination sera 15.",
,,,,,,,,
(*) = detected in some sequences but not all,,,,,,,,
"+These variants share one specific mutation called D614G. This mutation was one of the first documented in the US in the initial stages of the pandemic, after having initially circulated in Europe[13]. There is evidence that variants with this mutation spread more quickly than viruses without this mutation [12].",,,,,,,,
"a – Phylogenetic Assignment of Named Global Outbreak (PANGO) Lineages is software tool developed by members of the Rambaut Lab. The associated web application was developed by the Centre for Genomic Pathogen Surveillance in South Cambridgeshire and is intended to implement the dynamic nomenclature of SARS-CoV-2 lineages, known as the PANGO nomenclature.",,,,,,,,
"b – Nextstrain, a collaboration between researchers in Seattle, USA and Basel, Switzerland, provides open-source tools for visualizing the genetics of outbreaks. The goal is to support public health surveillance by facilitating understanding of the spread and evolution of pathogens.",,,,,,,,
"c – To assist with public discussions of variants, WHO proposed using labels consisting of the Greek Alphabet, i.e., Alpha, Beta, Gamma, as a practical way to discuss variants by non-scientific audiences. Tracking SARS-CoV-2 variants (who.int)external icon",,,,,,,,
"d – The Biodefense and Emerging Infections Research Resources (BEI Resources) is a NIAID-funded repository to provide reagents, tools, and information to the research community. The reference viruses proposed here facilitate the harmonization of information among all stakeholders in the COVID-19 pandemic research community. Please note that the reference viruses provided in the tables below are based on what is currently available through the BEI resources.",,,,,,,,
e  – Attributes listed are based on data available from pseudoviruses or recombinant viruses containing combinations of substitutions characteristic of specific lineages or from reference virus isolates.,,,,,,,,
,,,,,,,,
Selected Characteristics of SARS-CoV-2 Variants of Interest+,,,,,,,,
Name (Pango lineageexternal icon)a,Spike Protein Substitutions,Name (Nextstrainexternal iconexternal icon)b,WHO Labeld,First Detected,BEIexternal iconReference Isolatec,Attributes,,
B.1.525,"A67V, 69del, 70del, 144del, E484K, D614G, Q677H, F888L",20A/S:484K,Eta,United Kingdom/Nigeria – December 2020,,"Potential reduction in neutralization by some EUA monoclonal antibody treatments 7, 14",Potential reduction in neutralization by convalescent and post-vaccination sera 22,
B.1.526,"(L5F*), T95I, D253G, (S477N*), (E484K*), D614G, (A701V*)",20C/S:484K,Iota,United States (New York) – November 2020,NR-55359external icon,"Reduced susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment; however, the clinical implications of this are not known.7Alternative monoclonal antibody treatments are available.14","Reduced neutralization by convalescent and post-vaccination sera 22, 24",
B.1.526.1,"D80G, 144del, F157S, L452R, D614G, (T791I*), (T859N*), D950H",20C,,United States (New York) – October 2020,,"Potential reduction in neutralization by some EUA monoclonal antibody treatments 7, 14",Potential reduction in neutralization by convalescent and post-vaccination sera22,"Potential reduction in neutralization by some EUA monoclonal antibody treatments 7, 14"
B.1.617,"L452R, E484Q, D614G",20A,,India – February 2021,,"Reduced neutralization by post-vaccination sera 25, 26",,
B.1.617.1,"(T95I), G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H",20A/S:154K,Kappa,India – December 2020,,"Potential reduction in neutralization by some EUA monoclonal antibody treatments 7, 14",Potential reduction in neutralization by post-vaccination sera 26,
B.1.617.2,"T19R, (G142D), 156del, 157del, R158G, L452R, T478K, D614G, P681R, D950N",20A/S:478K,Delta,India – December 2020,,"Potential reduction in neutralization by some EUA monoclonal antibody treatments 7, 14",Potential reduction in neutralization by post-vaccination sera 21 ,
B.1.617.3,"T19R, G142D, L452R, E484Q, D614G, P681R, D950N",20A,,India – October 2020,,"Potential reduction in neutralization by some EUA monoclonal antibody treatments 7, 14",Potential reduction in neutralization by post-vaccination sera 26,
P.2,"E484K, (F565L*), D614G, V1176F",20J,Zeta,Brazil – April 2020,,"Potential reduction in neutralization by some EUA monoclonal antibody treatments 7, 14","Reduced neutralization by post-vaccination sera 22, 23",
,,,,,,,,
"+These variants share one specific mutation called D614G. This mutation was one of the first documented in the US in the initial stages of the pandemic, after having initially circulated in Europe[13]. There is evidence that variants with this mutation spread more quickly than viruses without this mutation [12external icon].",,,,,,,,
"a – Phylogenetic Assignment of Named Global Outbreak (PANGO) Lineages is software tool developed by members of the Rambaut Lab. The associated web application was developed by the Centre for Genomic Pathogen Surveillance in South Cambridgeshire and is intended to implement the dynamic nomenclature of SARS-CoV-2 lineages, known as the PANGO nomenclature. https://cov-lineages.org",,,,,,,,
"b – Nextstrain, a collaboration between researchers in Seattle, USA and Basel, Switzerland, provides open-source tools for visualizing the genetics of outbreaks. The goal is to support public health surveillance by facilitating understanding of the spread and evolution of pathogens. https://nextstrain.org",,,,,,,,
"c – The Biodefense and Emerging Infections Research Resources (BEI Resources) is a NIAID-funded repository to provide reagents, tools, and information to the research community. The reference viruses proposed here facilitate the harmonization of information among all stakeholders in the COVID-19 pandemic research community. Please note that the reference viruses provided in the tables below are based on what is currently available through the BEI Resources. https://www.beiresources.org/About/BEIResources.aspx",,,,,,,,
"d – To assist with public discussions of variants, WHO proposed using labels consisting of the Greek Alphabet, i.e., Alpha, Beta, Gamma, as a practical way to discuss variants by non-scientific audiences. Tracking SARS-CoV-2 variants (who.int)external icon",,,,,,,,
,,,,,,,,
Currently there are no SARS-CoV-2 variants that rise to the level of high consequence.,,,,,,,,